Frontiers in Immunology · 2022 · 41 citations · 134 references
Veterinary MedicineInfectious DiseasesPreventive MedicineImmunizationImmunology Of Infectious DiseasesVaccinologyVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyVaccine-preventable DiseasesViral VaccinesCoronavirus VaccinesEffectiveness Against Asymptomatic InfectionEffectiveness Against Symptomatic DiseaseEfficacy Against InfectionOverall Vaccine EffectivenessSars-cov-2 InfectionVaccine Effectiveness After BoostingVariant-specific Vaccine Effectiveness
It is urgently needed to update the comprehensive analysis about the efficacy or effectiveness of COVID-19 vaccines especially during the COVID-19 pandemic caused by SARS-CoV-2 Delta and Omicron variants. In general, the current COVID-19 vaccines showed a cumulative efficacy of 66.4%, 79.7%, and 93.6% to prevent SARS-CoV-2 infection, symptomatic COVID-19, and severe COVID-19, respectively, but could not prevent the asymptomatic infection of SARS-CoV-2. Furthermore, the current COVID-19 vaccines could effectively prevent COVID-19 caused by the Delta variant although the incidence of breakthrough infection of the SARS-CoV-2 Delta variant increased when the intervals post full vaccination extended, suggesting the waning effectiveness of COVID-19 vaccines. In addition, one-dose booster immunization showed an effectiveness of 74.5% to prevent COVID-19 caused by the Delta variant. However, current COVID-19 vaccines could not prevent the infection of Omicron sub-lineage BA.1.1.529 and had about 50% effectiveness to prevent COVID-19 caused by Omicron sub-lineage BA.1.1.529. Furthermore, the effectiveness was 87.6% and 90.1% to prevent severe COVID-19 and COVID-19-related death caused by Omicron sub-lineage BA.2, respectively, while one-dose booster immunization could enhance the effectiveness of COVID-19 vaccines to prevent the infection and COVID-19 caused by Omicron sub-lineage BA.1.1.529 and sub-lineage BA.2. Two-dose booster immunization showed an increased effectiveness of 81.8% against severe COVID-19 caused by the Omicron sub-lineage BA.1.1.529 variant compared with one-dose booster immunization. The effectiveness of the booster immunization with RNA-based vaccine BNT162b2 or mRNA-1273 was over 75% against severe COVID-19 more than 17 weeks after booster immunization whereas the heterogenous booster immunization showed better effectiveness than homologous booster immunization. In summary, the current COVID-19 vaccines could effectively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization could enhance protection capability, and two-dose booster immunization could provide additional protection against severe COVID-19.
134
Bias in meta-analysis detected by a simple, graphical test
Matthias Egger, George Davey Smith, Martin Schneider et al. · BMJ · 1997 · 56.3K citations
Meta-analysis in clinical trials
Rebecca DerSimonian, Nan M. Laird · Controlled Clinical Trials · 1986 · 39.3K citations